Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report released on Tuesday morning,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. Maxim Group decreased their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday.

Lineage Cell Therapeutics Trading Up 0.4 %

Shares of NYSEAMERICAN:LCTX opened at $0.53 on Tuesday. The company has a market capitalization of $117.46 million, a price-to-earnings ratio of -4.44 and a beta of 1.21. The stock’s fifty day moving average is $0.60. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Defender Capital LLC. lifted its stake in shares of Lineage Cell Therapeutics by 19.2% during the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after buying an additional 961,150 shares during the period. Geode Capital Management LLC lifted its position in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after acquiring an additional 83,274 shares during the period. Barclays PLC grew its stake in Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after purchasing an additional 159,924 shares during the last quarter. State Street Corp increased its holdings in shares of Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares during the period. Finally, Atria Wealth Solutions Inc. purchased a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth about $29,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.